Facebook
Twitter
LinkedIn
ForwardMiami Cancer Institute Multispecialty Grand Rounds: Breast Radiotherapy – Harnessing New Technology to Mitigate Toxicity
Over the past decade, breast cancer radiotherapy has increasingly focused on technology to improve treatment precision and limit toxicity. Rapid developments in the technological delivery of radiation-via both volumetric arc therapy and proton beam radiation have shown promise in improving target coverage and normal tissue sparing for breast cancer patients. Cutting-edge innovations, including MR-guided radiotherapy and FLASH technology, are now being explored as means to further improve treatment precision and decrease toxicity. The purpose of this talk is to highlight and discuss these advances in radiotherapy, review the existing evidence to support their use in the treatment of breast cancer, and detail specific patient populations that are most likely to benefit. Discussion will also focus on ongoing and future research aimed at improving our understanding and utilization of these novel advances in care.
This course will be live at MCI - 3N110 and Virtual
Target Audience
Oncologists, Radiation Oncologists, Hematology Oncologists, Radiation Therapists, Endocrinologists, Pulmonologists, Otolaryngologists, General Surgeons, General Practitioners, Obstetricians and Gynecologists, Nurses, Social Workers, Patient Navigators and all other interested healthcare professionals.
Learning Objectives
- Assess the current state and future possibilities for the use of MR-guided radiotherapy and FLASH technology for breast cancer.
- Analyze the history, physics/dosimetry and clinical potential of VMAT and proton therapy for mitigating the late effects of breast radiotherapy.
Rachel Jimenez, M.D.
Chair, Quality and Safety
Department of Radiation Oncology
Massachusetts General Hospital
Boston, Massachusetts
Rachel Jimenez, M.D., faculty for this educational activity, has received funding from the American Society of Clinical Oncology (ASCO), Breast Cancer Research Foundation (BCRF), and 5P01CA261669, the presentation or discussion will not include off-label or unapproved product usage.
Guilherme Rabinowits, M.D., conference series director, has indicated that he is an advisor with Sanofi-Genzyme, Regeneron, Castle and Boston Gene. All of the relevant financial relationships listed for this individual have been mitigated.
Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationship(s) to disclose with ineligible companies*
*Ineligible companies - Companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.
Baptist Health South Florida designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been approved for 1 credit hour, CE Broker Course #20-680158, by the Florida Boards of Medicine, Osteopathic Medicine and by the Florida Council of Physician Assistants.
This activity has also been approved for 1 credit hour for Nurse Practitioners, Nurses and Respiratory Therapists. Baptist Health South Florida CE Broker Provider #50-182.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 General certificate of attendance
- 1.00 Nurse Practitioners
- 1.00 Florida Board of Nursing
- 1.00 Florida Board of Respiratory Therapy
This course is available Live at MCI - 3N110 or Via Zoom Webinar. Please choose one of the options below.
Register for the live conference
Register for the virtual conference